-
F647997-2mgFiboflapon sodium (GSK2190915: AM-803) is a potent and orally bioavailable 5-lipoxygenase-activating protein ( FLAP ) inhibitor with a potency of 2.9 nM in FLAP binding, an IC 50 of 76 nM for inhibition of LTB4 in human bloodIn VitroFiboflapon
-
F647997-50mgFiboflapon sodium (GSK2190915: AM-803) is a potent and orally bioavailable 5-lipoxygenase-activating protein ( FLAP ) inhibitor with a potency of 2.9 nM in FLAP binding, an IC 50 of 76 nM for inhibition of LTB4 in human bloodIn VitroFiboflapon
-
F647997-5mgFiboflapon sodium (GSK2190915: AM-803) is a potent and orally bioavailable 5-lipoxygenase-activating protein ( FLAP ) inhibitor with a potency of 2.9 nM in FLAP binding, an IC 50 of 76 nM for inhibition of LTB4 in human bloodIn VitroFiboflapon
-
F655250-1mlFiboflapon sodium (GSK2190915: AM-803) is a potent and orally bioavailable 5-lipoxygenase-activating protein ( FLAP ) inhibitor with a potency of 2.9 nM in FLAP binding, an IC 50 of 76 nM for inhibition of LTB4 in human bloodIn VitroFiboflapon
-
F651787-10mgFidarestat (SNK 860) is an inhibitor of aldose reductase , with IC 50 s of 26 nM, 33 μM, and 1.8 μM for aldose reductase , AKR1B10 and V301L AKR1B10, respectively: Fidarestat (SNK 860) has the potential to treat diabetic disease.In VitroFidarestat
-
F651787-1mgFidarestat (SNK 860) is an inhibitor of aldose reductase , with IC 50 s of 26 nM, 33 μM, and 1.8 μM for aldose reductase , AKR1B10 and V301L AKR1B10, respectively: Fidarestat (SNK 860) has the potential to treat diabetic disease.In VitroFidarestat
-
F651787-5mgFidarestat (SNK 860) is an inhibitor of aldose reductase , with IC 50 s of 26 nM, 33 μM, and 1.8 μM for aldose reductase , AKR1B10 and V301L AKR1B10, respectively: Fidarestat (SNK 860) has the potential to treat diabetic disease.In VitroFidarestat
-
F656826-1mlFidarestat (SNK 860) is an inhibitor of aldose reductase , with IC 50 s of 26 nM, 33 μM, and 1.8 μM for aldose reductase , AKR1B10 and V301L AKR1B10, respectively: Fidarestat (SNK 860) has the potential to treat diabetic disease.In VitroFidarestat
-
F649416-100mgFIDAS-5 is a potent and orally active methionine S-adenosyltransferase 2A (MAT2A) inhibitor with an IC 50 of 2.1 μM. FIDAS-5 effectively competes against S-adenosylmethionine (SAM) for MAT2A binding. FIDAS-5 has anticancer activitiesIn VitroFIDAS-5
-
F649416-10mgFIDAS-5 is a potent and orally active methionine S-adenosyltransferase 2A (MAT2A) inhibitor with an IC 50 of 2.1 μM. FIDAS-5 effectively competes against S-adenosylmethionine (SAM) for MAT2A binding. FIDAS-5 has anticancer activitiesIn VitroFIDAS-5
-
F649416-1mgFIDAS-5 is a potent and orally active methionine S-adenosyltransferase 2A (MAT2A) inhibitor with an IC 50 of 2.1 μM. FIDAS-5 effectively competes against S-adenosylmethionine (SAM) for MAT2A binding. FIDAS-5 has anticancer activitiesIn VitroFIDAS-5
-
F649416-250mgFIDAS-5 is a potent and orally active methionine S-adenosyltransferase 2A (MAT2A) inhibitor with an IC 50 of 2.1 μM. FIDAS-5 effectively competes against S-adenosylmethionine (SAM) for MAT2A binding. FIDAS-5 has anticancer activitiesIn VitroFIDAS-5